## Performance in Inititiating Quarter 4 2018-19

Research Ethics	Integrated Research	Submission Type	Name of Trial	First	Date of First	Duration	Duration	Duration	Date Site	Date Site	HRA	Date Site	Date Site	Non-	Date Site	A- B-	C - Closed	D-	E - Staff	F - No	G - No	H-	I - Rare	J - Other	Comment	Reasons
Committee Reference Number	Application System Number	,		Participant Recruited?	Participant Recruited	between Date Site Selected and Date	between Date Site Confirmed and First	between Date Site Selected and First	Invited	Selected	Approval Date	Confirmed By Sponsor	Confirmed	Confirmatio n Status	Ready To Start	Permissio Suspende ns d by delayed/d sponsor enied	by sponsor	Sponsor Delays	availabilit y issues	patients seen	patients consented	Contracti ng delays	diseases	\$		for delay correspon d to:
						Site Confirmed	Participant Recruited	Participant Recruited																		
18/SC/0095	235876	HRA Approval	BREEZE-AD4 - Baricitinib in moderate to severe atopic dermatitis	Yes	28/03/2019	31	322	353	06/09/2017	09/04/2018	05/04/2018	26/04/2018	10/05/2018	Please Select	14/05/2018						Y			5	Difficult study to recruit to	NHS Provider
			A Phase 3, Multicenter, Double- Blind, Randomized, Placebo- Controlled Study Evaluating the Safety and Efficacy of Barcitinib in Combination with Topical Corticosteroids in Patients with Moderate to Severe Atopic Dermatitis who have Experienced Failure to Cyclosporine or are Intolerant to, or have Contraindication to Cyclosporine																							
18/LO/0813	247105	HRA Approval	IDDSI Level 2 ONS study -	No		203			01/02/2018	06/04/2018	28/08/2018	16/07/2018	26/10/2018	Please	26/10/2018	Y										Sponsor
			IDDSIL2  An evaluation of the tolerance, compliance, acceptability and safety of a new oral nutritional supplement in dysphagic patients											Select										: :	delayed due to Sponsor, as changes required	
4.455.4400	454000		a cruo		20/44/2040		100	107	44 (04 (0040	40 (05 (0040	40/00/2046	44 (05 (0040	40 107 10040		0.4/4.0/204.0									i	REC/HRA.	0.4
14/EE/1293	164389	HRA Approval	C-STICH The Cerclage Suture Type for an Insufficient Cervix and its effect on Health outcomes	Yes	23/11/2018	61	136	197	11/01/2018	10/05/2018	10/08/2016	11/06/2018	10/07/2018	Please Select	04/10/2018			Y	Y			Y		5	delays with sponsor sending the	Both
16/WM/0036	180476	HRA Approval	GBS2	Yes	11/02/2019	151	97	248	01/06/2018	08/06/2018	23/08/2016	01/11/2018	06/11/2018	Please	10/12/2018	Y				Y				ĺ	Delays at	NHS
			Accuracy of a rapid intrapartum test for maternal group B strept											Select											site regarding	Provider
			ococcal colonisation and its pot ential to reduce																						microbiol ogy	
			antibiotic usage in mothers with risk factors.	1																				1	support for the	
16/NS/0106	212541	HRA Approval	RAACENO - Reducing Asthma	No		35			24/11/2016	24/07/2018	04/04/2017	03/08/2018	28/08/2018	Please	31/08/2018	Υ				Υ				1		NHS
			Attacks in Children using Exhaled Nitric Oxide as a biomarker to inform treatment strategy - a randomised trial											Select										i c	with Trust IT approval of App to be	Provider
17/YH/0120	208838	HRA Approval	DISC - Dupuytren's Interventions Surgery vs Collagenase	No		131			13/11/2017	01/08/2018	25/05/2017	03/12/2018	10/12/2018	Please Select	21/12/2018				Y		Y			1	installed Delays due to pharmacy	NHS Provider
15/NI/0161	184748	HRA Approval	EASI-SWITCH v1.0 - Early switch to oral antibiotic therapy in patients with low risk neutropenic sepsis	Yes	12/03/2019	75	154	229	22/05/2018	26/07/2018	03/08/2016	01/11/2018	09/10/2018	Please Select	01/11/2018			Υ		Υ				1	date missing for Sponsor	Sponsor
17/EE/0368	213669	HRA Approval	STRESS L - Study into the	No		209			12/04/2018	22/06/2018	10/11/2017	15/01/2019	17/01/2019	Please	12/03/2019				v						to confirm Delays	NHS
,,			Reversal of Septic Shock with Landiolol (Beta Blockade)							,,	,,	,,	,,	Select	,,										due to pharmacy capacity.	Provider
18/SC/0210	239572	HRA Approval	EFFICACY AND SAFETY OF PF- 04965842 200 MG AND 100 MG QD MONOTHERAPY IN SUBJECTS WITH AD	No		10			13/10/2017	14/09/2018	02/08/2018	14/09/2018	24/09/2018	Please Select	23/10/2018			Y	Y	Y				9	set-up due to pharmacy	Both
18/EM/0281	251974	HRA Approval	ECZTEND - Tralokinumab in moderate-severe AD extension	Yes	13/12/2018	14	15	29	24/05/2018	14/11/2018	14/11/2018	14/11/2018	28/11/2018	Please Select	28/11/2018										staff	Please Select
18/WM/0347	250624	HRA Approval	trial 1337 A Phase 3 study of BMS-986165	No					15/03/2018	10/01/2019	10/01/2019			Please Select				Y								Sponsor
40/4044/0040	ar chao		in participants with plaque psoriasis						00 (05 (0040	24 (24 (224	4 6 /04 /0040															e.
18/NW/0813	256738	HRA Approval	CAIN457M2302 (SUNRISE): Secukinumab in hidradenitis suppurativa	No					09/05/2018	21/01/2019	16/01/2019			Please Select												Please Select
18/YH/0027	223937	HRA Approval	UK CLL Long-term Follow-up Study	No		182			04/07/2018	04/07/2018	16/02/2018	02/01/2019	02/01/2019	Please Select										Ī		Please Select
17/LO/0962	220190	HRA Approval	Helping Pregnant smokers to quit: A multi-centre RCT of electronic cigarettes vs. nicotine patches (usual care)	No 2		30			21/05/2018	14/11/2018	24/07/2017	14/12/2018	14/12/2018	Please Select	14/12/2018				Y		Y					NHS Provider
18/SC/0454	249509	HRA Approval	POISE-3 - Perioperative	No					03/09/2018	30/11/2018	16/01/2019			Please					Y						Pharmacy	
			Ischemic Evaluation-3 Trial					<u> </u>		<u> </u>	<u> </u>			Select											delays at site.	Provider